Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer

JF. Fahrmann, LE. Bantis, M. Capello, G. Scelo, JB. Dennison, N. Patel, E. Murage, J. Vykoukal, DL. Kundnani, L. Foretova, E. Fabianova, I. Holcatova, V. Janout, Z. Feng, M. Yip-Schneider, J. Zhang, R. Brand, A. Taguchi, A. Maitra, P. Brennan, C....

. 2019 ; 111 (4) : 372-379. [pub] 20190401

Language English Country United States

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20006794

Grant support
P50 CA221707 NCI NIH HHS - United States
U01 CA196403 NCI NIH HHS - United States
U01 CA200468 NCI NIH HHS - United States
U24 CA086368 NCI NIH HHS - United States

BACKGROUND: We applied a training and testing approach to develop and validate a plasma metabolite panel for the detection of early-stage pancreatic ductal adenocarcinoma (PDAC) alone and in combination with a previously validated protein panel for early-stage PDAC. METHODS: A comprehensive metabolomics platform was initially applied to plasmas collected from 20 PDAC cases and 80 controls. Candidate markers were filtered based on a second independent cohort that included nine invasive intraductal papillary mucinous neoplasm cases and 51 benign pancreatic cysts. Blinded validation of the resulting metabolite panel was performed in an independent test cohort consisting of 39 resectable PDAC cases and 82 matched healthy controls. The additive value of combining the metabolite panel with a previously validated protein panel was evaluated. RESULTS: Five metabolites (acetylspermidine, diacetylspermine, an indole-derivative, and two lysophosphatidylcholines) were selected as a panel based on filtering criteria. A combination rule was developed for distinguishing between PDAC and healthy controls using the Training Set. In the blinded validation study with early-stage PDAC samples and controls, the five metabolites yielded areas under the curve (AUCs) ranging from 0.726 to 0.842, and the combined metabolite model yielded an AUC of 0.892 (95% confidence interval [CI] = 0.828 to 0.956). Performance was further statistically significantly improved by combining the metabolite panel with a previously validated protein marker panel consisting of CA 19-9, LRG1, and TIMP1 (AUC = 0.924, 95% CI = 0.864 to 0.983, comparison DeLong test one-sided P= .02). CONCLUSIONS: A metabolite panel in combination with CA19-9, TIMP1, and LRG1 exhibited substantially improved performance in the detection of early-stage PDAC compared with a protein panel alone.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006794
003      
CZ-PrNML
005      
20200522111044.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/jnci/djy126 $2 doi
035    __
$a (PubMed)30137376
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fahrmann, Johannes F $u Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX.
245    12
$a A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer / $c JF. Fahrmann, LE. Bantis, M. Capello, G. Scelo, JB. Dennison, N. Patel, E. Murage, J. Vykoukal, DL. Kundnani, L. Foretova, E. Fabianova, I. Holcatova, V. Janout, Z. Feng, M. Yip-Schneider, J. Zhang, R. Brand, A. Taguchi, A. Maitra, P. Brennan, C. Max Schmidt, S. Hanash,
520    9_
$a BACKGROUND: We applied a training and testing approach to develop and validate a plasma metabolite panel for the detection of early-stage pancreatic ductal adenocarcinoma (PDAC) alone and in combination with a previously validated protein panel for early-stage PDAC. METHODS: A comprehensive metabolomics platform was initially applied to plasmas collected from 20 PDAC cases and 80 controls. Candidate markers were filtered based on a second independent cohort that included nine invasive intraductal papillary mucinous neoplasm cases and 51 benign pancreatic cysts. Blinded validation of the resulting metabolite panel was performed in an independent test cohort consisting of 39 resectable PDAC cases and 82 matched healthy controls. The additive value of combining the metabolite panel with a previously validated protein panel was evaluated. RESULTS: Five metabolites (acetylspermidine, diacetylspermine, an indole-derivative, and two lysophosphatidylcholines) were selected as a panel based on filtering criteria. A combination rule was developed for distinguishing between PDAC and healthy controls using the Training Set. In the blinded validation study with early-stage PDAC samples and controls, the five metabolites yielded areas under the curve (AUCs) ranging from 0.726 to 0.842, and the combined metabolite model yielded an AUC of 0.892 (95% confidence interval [CI] = 0.828 to 0.956). Performance was further statistically significantly improved by combining the metabolite panel with a previously validated protein marker panel consisting of CA 19-9, LRG1, and TIMP1 (AUC = 0.924, 95% CI = 0.864 to 0.983, comparison DeLong test one-sided P= .02). CONCLUSIONS: A metabolite panel in combination with CA19-9, TIMP1, and LRG1 exhibited substantially improved performance in the detection of early-stage PDAC compared with a protein panel alone.
650    _2
$a mucinózní adenokarcinom $x genetika $x metabolismus $x patologie $7 D002288
650    _2
$a nádorové biomarkery $x krev $x genetika $7 D014408
650    _2
$a duktální karcinom slinivky břišní $x genetika $x metabolismus $x patologie $7 D021441
650    _2
$a papilární karcinom $x genetika $x metabolismus $x patologie $7 D002291
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    12
$a metabolom $7 D055442
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a staging nádorů $7 D009367
650    _2
$a nádory slinivky břišní $x genetika $x metabolismus $x patologie $7 D010190
650    12
$a transkriptom $7 D059467
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bantis, Leonidas E $u Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
700    1_
$a Capello, Michela $u Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX.
700    1_
$a Scelo, Ghislaine $u International Agency for Research on Cancer (IARC), Lyon, France.
700    1_
$a Dennison, Jennifer B $u Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX.
700    1_
$a Patel, Nikul $u Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX.
700    1_
$a Murage, Eunice $u Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX.
700    1_
$a Vykoukal, Jody $u Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX.
700    1_
$a Kundnani, Deepali L $u Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX.
700    1_
$a Foretova, Lenka $u Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Fabianova, Eleonora $u Regional Authority of Public Health in Banska Bystrica, Banska Bystrica, Slovakia. Catholic University, Faculty of Healthy, Ružomberok, Slovakia.
700    1_
$a Holcatova, Ivana $u Institute of Public Health and Preventive Medicine, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Janout, Vladimir $u Faculty of Medicine, Palacky University, Olomouc, Czech Republic.
700    1_
$a Feng, Ziding $u Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
700    1_
$a Yip-Schneider, Michele $u Department Surgery, Indiana University School of Medicine, Indianapolis, IN.
700    1_
$a Zhang, Jianjun $u Department of Epidemiology, Fairbanks School of Public Health, Indiana University, Indianapolis, IN.
700    1_
$a Brand, Randall $u Department of Medicine, University of Pittsburgh, Pittsburgh, PA.
700    1_
$a Taguchi, Ayumu $u Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
700    1_
$a Maitra, Anirban $u Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
700    1_
$a Brennan, Paul $u International Agency for Research on Cancer (IARC), Lyon, France.
700    1_
$a Max Schmidt, C $u Department Surgery, Indiana University School of Medicine, Indianapolis, IN.
700    1_
$a Hanash, Samir $u Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX.
773    0_
$w MED00003002 $t Journal of the National Cancer Institute $x 1460-2105 $g Roč. 111, č. 4 (2019), s. 372-379
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30137376 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200522111042 $b ABA008
999    __
$a ok $b bmc $g 1525652 $s 1096850
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 111 $c 4 $d 372-379 $e 20190401 $i 1460-2105 $m Journal of the National Cancer Institute $n J Natl Cancer Inst $x MED00003002
GRA    __
$a P50 CA221707 $p NCI NIH HHS $2 United States
GRA    __
$a U01 CA196403 $p NCI NIH HHS $2 United States
GRA    __
$a U01 CA200468 $p NCI NIH HHS $2 United States
GRA    __
$a U24 CA086368 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20200511

Find record

Citation metrics

Archiving options